Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,

Published byMarvin Holland Modified over 9 years ago

Similar presentations

Presentation on theme: "Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,"— Presentation transcript:

1 Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1, Tadashi Hasegawa 2, Tadakazu Shimoda 2, Yasuo Beppu 4, Akira Kawai 4, Setsuo Hirohashi 1, Tadashi Kondo 1 1. Proteome Bioinformatics Project, National Cancer Center Research Institute, Tokyo, Japan 2. Clinical Laboratory Division, National Cancer Center Research Hospital, Tokyo, Japan 3. Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo, Japan 4. Orthopedic Surgery Division, National Cancer Center Hospital, Tokyo, Japan

2 MW(KDa) Isoelectric focusing 80 56 36 30 18 pH 4.0 pH 7.0 Procedure of Proteomics Study 1500-2000 spots Protein was extracted and labeled with CyDye 2D-Image Data-Mining Protein spots were identified High-speed/-throughput 1D-RP mLC/NSI-MS/MS Analysis Mass SpectrometrySurgical Specimen

3 Back Ground (GISTs) GISTs are the most common primary mesenchymal tumor of the digestive tract. It is genetically characterized by the presence of mutations and overexpression of KIT and, clinically, characterized by their significant response to treatment with imatinib. However, there are certain populations of patients who can be treated only by simple resection and do not need imatinib treatment. The aim of this study is to develop prognostic biomarkers for GISTs, by means of proteomic approach, and identify high- risk patients who would need further adjuvant treatment such as imatinib.

4 Strategy “Poor prognosis GISTs” = Metastasis within 1 year (8 samples) “Good prognosis GISTs” = No-metastasis over 2 years Low or IM Risk group * (9 samples) ＊ Pathological factors ( Risk Classification-> Hasegawa T. et al: Human Pathology. 2002 ) vs Identify the informative spots Confirmed these results Western-blot, Immunochemical study Large-scale sample set (Immunohistochemical study) Verified the power of biomarker

5 Cluster Analysis 43 spots (p < 0.01) Poor-prognosis GISTs Good-prognosis GISTs Pfetin 1513 spots 43 spots Wilcoxon test Poor-prognosis GISTs Metastasis within 1 year (samples 1-8) Good-prognosis GISTs No-metastasis over 2 years Low or IM Risk group (samples 9-17)

6

7 Immunohistochemical study (Pfetin antibody) Western Blotting Poor prognosis GISTs Good prognosis GISTs (Pfetin antibody) Good prognosis GISTs Poor prognosis GISTs

8 210 cases, M0, primary samples Metastasis-Free Survival of the M0 GISTs Patients According to the Expression of Pfetin (NCC :210 cases) Suehara Y et al. Clin Cancer Res (2008) 14: 1707- 1717 Nature Clinical Practice Oncology (2008) 5, 364- 365 5-year: 93.9% 5-year: 36.2% P < 0.0001 (Immunohistochemical Study)

9 Overall Survival of the M0 GISTs Patients According to the Expression of Pfetin (NCC :210 cases) Suehara Y et al. Clin Cancer Res (2008) 14: 1707- 1717 Nature Clinical Practice Oncology (2008) 5, 364- 365 P < 0.0001 5-year: 97.2% 5-year: 76.5% 210 cases, M0, primary samples (Immunohistochemical Study)

10 Metastasis-Free Survival Curve of GISTs According to Risk Classification (NCC :210 cases) N=110 N=46 N=54 High risk Suehara Y et al. Clin Cancer Res (2008) 14: 1707-1717 Nature Clinical Practice Oncology (2008) 5, 364-365 Intermediate risk Low risk

11 Metastasis-Free Survival Curve of GISTs According to Pfetin Immunochemical Stain (NCC :210 cases) High risk N=110 N=46 N=54 Pfetin positive (N=100) Pfetin positive (N=27) Pfetin positive (N=44) Pfetin negative (N=10) Pfetin negative (N=2) Pfetin negative (N=27) P = 0.0002 Suehara Y et al. Clin Cancer Res (2008) 14: 1707-1717 Nature Clinical Practice Oncology (2008) 5, 364-365 Intermediate risk Low risk P<0.0001 P=0.0109 P=0.0002

12 Multivariate Analysis of Metastasis Free Survival by Cox Regression

13 Conclusion We examined the proteomic profile of GISTs according to prognosis using both 2D-DIGE and clinical data.We examined the proteomic profile of GISTs according to prognosis using both 2D-DIGE and clinical data. Pfetin expression was a significant predictor for metastasis and survival of patients with GISTs.Pfetin expression was a significant predictor for metastasis and survival of patients with GISTs. Pfetin can be a strong candidate for a biomarker to predict the metastasis in GISTs patients.Pfetin can be a strong candidate for a biomarker to predict the metastasis in GISTs patients.

Download ppt "Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,"

Similar presentations

CD10, scored as positive versus negative all path 1 path 2 path 3 path 4 path 5 path 6 path 7 path 8 path 9 CD10 can be reproducibly scored, but is very.

CD10, scored as positive versus negative all path 1 path 2 path 3 path 4 path 5 path 6 path 7 path 8 path 9 CD10 can be reproducibly scored, but is very.
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.

Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.

Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in chondrosarcomas Makoto Endo, 1 Tadaki Matsumura, 2 Umio Yamaguchi, 1 Fumihiko.

Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in chondrosarcomas Makoto Endo, 1 Tadaki Matsumura, 2 Umio Yamaguchi, 1 Fumihiko.
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,

Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,
Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo.

Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo.
CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;

CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Resistance to TK inhibitors: KIT and PDGFRA Maria Debiec-Rychter, M.D., Ph.D. Center for Human Genetics, KULeuven, Belgium ESMO meeting Milan, May 13th,

Resistance to TK inhibitors: KIT and PDGFRA Maria Debiec-Rychter, M.D., Ph.D. Center for Human Genetics, KULeuven, Belgium ESMO meeting Milan, May 13th,
MammaPrint, the story of the 70-gene profile

MammaPrint, the story of the 70-gene profile
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Musculoskeletal Oncology Service, National Cancer Center Hospital Musculoskeletal Oncology Service, Keio University Hospital An Analysis of Clinicopathological.

Musculoskeletal Oncology Service, National Cancer Center Hospital Musculoskeletal Oncology Service, Keio University Hospital An Analysis of Clinicopathological.
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.

Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.

THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.
Predictive Biomarkers for Lung Cancer Current Status / Perspectives: Although curative resection of patients with early-stage lung CA are performed, the.

Predictive Biomarkers for Lung Cancer Current Status / Perspectives: Although curative resection of patients with early-stage lung CA are performed, the.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
G.Liguori,G.Pirozzi^, I. Forte, G.Botti, R.Franco, A.La Rocca*, G.Rocco* Istituto Nazionale Tumori Napoli Dip.Anatomia Patologica; Dip.Onc.Sperimentale^;

G.Liguori,G.Pirozzi^, I. Forte, G.Botti, R.Franco, A.La Rocca*, G.Rocco* Istituto Nazionale Tumori Napoli Dip.Anatomia Patologica; Dip.Onc.Sperimentale^;
A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.

A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.

Similar presentations

Ads by Google